Additional studies are needed to prove whether the dynamic monitoring of abnormal Ptgds expression and the resultant metabolic disorders are reproducible in humans, which may have greater potential for climacteric syndrome predication and therapeutic evaluation as an effective methodological strategy. The gene discussed is PTGDS; the disease is metabolic disease.